Hans-Ulrich Dermuth

Title: The Innovations of Hans-Ulrich Dermuth

Introduction

Hans-Ulrich Dermuth is a notable inventor based in Munich, Germany. He has made significant contributions to the field of biochemistry, particularly in the area of enzyme inhibitors. His work has implications for the development of new therapeutic agents.

Latest Patents

Hans-Ulrich Dermuth holds a patent for a screening method for enzyme inhibitors. This patent focuses on novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5). The patent also includes isolated nucleic acids coding for these isoenzymes. These innovations are useful for discovering new therapeutic agents, measuring cyclase activity, and determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes. He has 1 patent to his name.

Career Highlights

Hans-Ulrich Dermuth is associated with Probiodrug AG, a company that focuses on developing innovative therapies for neurodegenerative diseases. His work at Probiodrug AG has been instrumental in advancing research in this critical area of medicine.

Collaborations

Throughout his career, Hans-Ulrich Dermuth has collaborated with esteemed colleagues, including Stephan Schilling and Holger Cynis. These collaborations have further enriched his research and contributed to the advancement of their shared goals in biochemistry.

Conclusion

Hans-Ulrich Dermuth's contributions to the field of enzyme inhibitors and his innovative patent work highlight his importance as an inventor. His ongoing efforts at Probiodrug AG continue to pave the way for new therapeutic developments.